Gallium-67 (Ga-67) is a versatile gamma-emitting radionuclide with a 78-hour physical half-life, widely employed in SPECT imaging for tumor detection, infection localization, and targeted radiopharmaceutical development. At Protheragen, our specialized radiochemistry team delivers precision Ga-67 radiolabeling solutions tailored to advance your preclinical and clinical research programs, from small-molecule conjugates to complex antibody-based tracers.
Gallium-67 is a cyclotron-produced radionuclide that decays by electron capture, emitting gamma photons at 93, 185, 288, and 394 keV—energies well-suited for single-photon emission computed tomography (SPECT). With a physical half-life of approximately 78 hours (3.26 days), Ga-67 offers a significantly longer imaging window compared to many other diagnostic radionuclides, making it particularly valuable for studying biological processes with extended pharmacokinetics, such as antibody biodistribution and tumor accumulation over multiple days. The trivalent Ga³⁺ ion exhibits chemical behavior analogous to ferric iron, enabling both direct utilization as gallium citrate for infection and lymphoma imaging and complexation with bifunctional chelators for targeted molecular imaging.
Fig 1. Effects of reaction temperature (A), reaction time (B) and peptide amount (C) on radiolabeling yield of 67Ga-NODAGA-GGNle-CycMSHhex. (Xu, Jingli, et al., 2020)
The radiolabeling of biomolecules with Ga-67 relies on bifunctional chelating agents that coordinate the metal ion while maintaining the biological targeting properties of the carrier molecule. Macrocyclic ligands such as NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid) and DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) have emerged as the cornerstone of Ga-67 coordination chemistry. NOTA, in particular, is regarded as the benchmark chelator for gallium radionuclides due to its exceptionally high thermodynamic stability (log K ≈ 31.0), allowing for mild labeling conditions—often at room temperature with incubation times under one hour—while preserving the structural integrity of heat-sensitive biomolecules such as proteins and peptides. Unlike its positron-emitting counterpart Ga-68, which demands rapid labeling protocols to accommodate a 68-minute half-life, Ga-67 affords researchers the flexibility to optimize reaction parameters for maximum complex stability and specific activity, a critical advantage when developing long-circulating radiopharmaceuticals for in vivo applications.
| Parameter | Ga-67 (SPECT) | Ga-68 (PET) | Clinical / Research Relevance |
|---|---|---|---|
| Physical Half-Life | 78 hours (3.26 days) | 68 minutes | Ga-67 enables multi-day imaging; Ga-68 suits same-day workflows |
| Primary Decay Mode | Electron capture (γ + Auger e⁻) | Positron emission (β⁺) | Ga-67 offers Auger therapy potential; Ga-68 provides PET resolution |
| Production Route | Cyclotron (Zn-68 target) | Generator (Ge-68/Ga-68) or cyclotron | Ga-67 requires dedicated cyclotron; Ga-68 offers on-site elution |
| Imaging Modality | SPECT / SPECT-CT | PET / PET-CT | SPECT is widely accessible; PET offers superior sensitivity |
| Gold-Standard Chelator | NOTA (room temp, <1 h) | NOTA (room temp, 5–10 min) | NOTA delivers highest Ga complex stability across both isotopes |
| Alternative Chelator | DOTA, DFO, THP, DTPA | DOTA, HBED-CC, NODAGA | DOTA enables theranostic pairing with Lu-177 and Y-90 |
| Typical pH for Labeling | pH 4–5.5 (NOTA); pH 3–5.5 (DOTA) | pH 3.5–4 (DOTA); pH 4–6.5 (NOTA) | Milder conditions preserve biomolecule integrity |
| Optimal Temperature | 25–37°C (NOTA); 80–100°C (DOTA) | 25–60°C (NOTA); 80–95°C (DOTA) | Ga-67 tolerates extended heating for DOTA conjugates |
| Key Clinical Applications | Infection, lymphoma, antibody imaging | Neuroendocrine tumors, prostate cancer (PSMA) | Ga-67 remains essential where PET is unavailable |
| Theranostic Pairing | Imaging partner for Lu-177, Y-90, Tb-161 | Imaging partner for Lu-177, Ac-225, Tb-161 | Shared chelator chemistry streamlines vector development |
| Radiation Dosimetry | ~0.113 mSv/MBq (citrate form) | Lower per-GBq burden due to short half-life | Ga-67 mAb dosimetry is manageable within therapy context |
| Emerging Research Focus | Auger electron therapy, long-circulating vectors | Kit-based formulations, automated synthesis | Ga-67 is re-emerging for preclinical theranostic pipelines |
Protheragen operates a dedicated radiochemistry facility equipped for the full spectrum of Ga-67 radiolabeling—from chelator conjugation and radiometal complexation to rigorous quality control and in vitro stability validation. Whether your program requires a simple Ga-67-citrate formulation for infection imaging or a sophisticated antibody-DOTA conjugate for theranostic development, our multidisciplinary team of radiochemists, analytical scientists, and quality assurance professionals ensures that every batch meets the exacting standards demanded by preclinical research and early-phase clinical trials. We support both standalone radiolabeling contracts and integrated CRDMO engagements, seamlessly bridging discovery chemistry with in vivo evaluation.
A successful Ga-67 radiolabeling campaign follows a structured, phase-gated workflow that balances radiochemical efficiency with biomolecular integrity. Each stage is designed to deliver a radioconjugate of defined purity, stability, and biological activity, ready for in vitro or in vivo evaluation.
1. Project Consultation & Feasibility Assessment: Our radiochemistry team reviews your targeting vector, proposed chelator, and intended application to define a customized labeling strategy. We evaluate biomolecular stability, anticipated specific activity requirements, and compatibility with Ga-67 chemistry to establish realistic milestones and deliverables.
2. Chelator Conjugation & Conjugate Characterization: The selected bifunctional chelator is covalently attached to the biomolecule under controlled conditions. The resulting conjugate is purified and characterized by mass spectrometry and chromatographic methods to confirm chelator-to-biomolecule stoichiometry and structural integrity.
3. Radiolabeling Condition Optimization: Ga-67 chloride is complexed with the chelator-conjugated biomolecule in a buffered reaction mixture. Parameters including pH, temperature, incubation time, and metal-to-ligand ratio are systematically optimized to achieve >95% radiochemical yield while preserving biological function.
4. Purification & Radiochemical Purity Verification: The crude reaction mixture is purified by size-exclusion chromatography or HPLC to remove unbound Ga-67 and colloidal species. Radiochemical purity is confirmed by ITLC-SG and HPLC with radioflow detection, ensuring the final product meets predefined release criteria.
5. in vitro Stability & Biological Validation: In vitro stability is assessed in serum and challenge solutions over 24–72 hours. Cell binding, internalization, and competitive inhibition assays are performed on relevant cell lines to confirm that radiolabeling has not compromised target affinity or specificity.
6. Formulation Development & Stability Profiling: The radioconjugate is formulated in a buffer system selected to maximize shelf-life and minimize radiolytic degradation. Accelerated and real-time stability studies are initiated to support subsequent in vivo use or regulatory submissions.
7. Preclinical Biodistribution & Imaging (Optional): For integrated CRDMO engagements, the Ga-67-labeled vector is administered to animal models to generate biodistribution data, SPECT-CT images, and preliminary dosimetry estimates that inform clinical translation strategy.
8. Batch Release & Documentation Package: A comprehensive batch record is compiled, including radiochemical purity certificates, stability data, in vitro validation results, and formulation specifications. All documentation is prepared to support preclinical study reports and early-phase clinical trial applications.
Whether you are developing a novel Ga-67-labeled antibody for theranostic imaging or require a reliable radiochemistry partner to support your preclinical research pipeline, Protheragen is ready to help you achieve your goals. Reach out to us today to discuss your project requirements, receive a customized proposal, or schedule a consultation with our radiochemistry specialists. We look forward to collaborating with you to advance the next generation of targeted radiopharmaceuticals.
Reference